Literature DB >> 19658180

Interobserver reproducibility of histologic parameters of melanoma deposits in sentinel lymph nodes: implications for management of patients with melanoma.

Rajmohan Murali1, Alistair J Cochran, Martin G Cook, Joseph D Hillman, Rooshdiya Z Karim, Marc Moncrieff, Hans Starz, John F Thompson, Richard A Scolyer.   

Abstract

BACKGROUND: : Histologic parameters of melanoma deposits in sentinel lymph nodes (SLNs) have been shown to be predictive of clinical outcome and the presence or absence of tumor in non-SLNs, but assessment of these parameters is prone to interobserver variation.
METHODS: : Histologic sections of 44 SLNs containing metastatic melanoma were examined by 7 pathologists. Parameters assessed included cross-sectional area of tumor deposits, cross-sectional area of SLNs, percentage of SLN area involved by tumor calculated from the 2 previous parameters, estimated percentage of SLN area involved by tumor, tumor penetrative depth, location of tumor within the SLN, and presence of extracapsular spread. Levels of interobserver agreement were measured by using intraclass correlation coefficients (ICC).
RESULTS: : There was good to excellent interobserver agreement on measurement of quantitative parameters: maximal size of largest tumor deposits, calculated area of 3 largest tumor deposits, percentage of the area of SLN involved by tumor, and tumor penetrative depth (ICC, 0.88, 0.73, 0.68, and 0.83, respectively). There was moderate agreement on the evaluation of subcapsular versus nonsubcapsular location of tumor deposits (ICC = 0.50). Agreement on assessment of extracapsular spread was fair (ICC = 0.39).
CONCLUSIONS: : Assessment of some of the quantitative parameters was highly reproducible between pathologists. However, evaluation of the location of tumor deposits within SLNs and assessment of extracapsular spread was less reproducible. Clearer definitions and training can be expected to improve the reproducibility of assessment. These results have important implications for reliability and reproducibility of these parameters in staging, prediction of outcome, and clinical management of melanoma patients. Cancer 2009. (c) 2009 American Cancer Society.

Entities:  

Mesh:

Year:  2009        PMID: 19658180      PMCID: PMC2767474          DOI: 10.1002/cncr.24298

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  46 in total

1.  Prognostic importance of lymph node tumor burden in melanoma patients staged by sentinel node biopsy.

Authors:  Jaime M Ranieri; Jeffrey D Wagner; Rafael Azuaje; D Davidson; Stacie Wenck; Joanne Fyffe; John J Coleman
Journal:  Ann Surg Oncol       Date:  2002-12       Impact factor: 5.344

Review 2.  Cutaneous melanoma.

Authors:  John F Thompson; Richard A Scolyer; Richard F Kefford
Journal:  Lancet       Date:  2005 Feb 19-25       Impact factor: 79.321

3.  The Sydney Melanoma Unit experience of sentinel lymphadenectomy for melanoma.

Authors:  J F Thompson
Journal:  Ann Surg Oncol       Date:  2001-10       Impact factor: 5.344

4.  A micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma.

Authors:  H Starz; B R Balda; K U Krämer; H Büchels; H Wang
Journal:  Cancer       Date:  2001-06-01       Impact factor: 6.860

5.  Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.

Authors:  C M Balch; S J Soong; J E Gershenwald; J F Thompson; D S Reintgen; N Cascinelli; M Urist; K M McMasters; M I Ross; J M Kirkwood; M B Atkins; J A Thompson; D G Coit; D Byrd; R Desmond; Y Zhang; P Y Liu; G H Lyman; A Morabito
Journal:  J Clin Oncol       Date:  2001-08-15       Impact factor: 44.544

6.  Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma.

Authors:  J D Wagner; M S Gordon; T Y Chuang; J J Coleman; J T Hayes; S H Jung; C Love
Journal:  Cancer       Date:  2000-07-15       Impact factor: 6.860

7.  Reliability of sentinel lymph node biopsy for staging melanoma.

Authors:  L Jansen; O E Nieweg; J L Peterse; C A Hoefnagel; R A Olmos; B B Kroon
Journal:  Br J Surg       Date:  2000-04       Impact factor: 6.939

8.  Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: review of a large single-institutional experience with an emphasis on recurrence.

Authors:  B M Clary; M S Brady; J J Lewis; D G Coit
Journal:  Ann Surg       Date:  2001-02       Impact factor: 12.969

9.  Predicting residual lymph node basin disease in melanoma patients with sentinel lymph node metastases.

Authors:  George I Salti; Tapas K Das Gupta
Journal:  Am J Surg       Date:  2003-08       Impact factor: 2.565

10.  Prediction of nonsentinel lymph node status in melanoma.

Authors:  Mark E Reeves; Ruby Delgado; Klaus J Busam; Mary S Brady; Daniel G Coit
Journal:  Ann Surg Oncol       Date:  2003 Jan-Feb       Impact factor: 5.344

View more
  9 in total

1.  The impact of nodal tumour burden on lymphoscintigraphic imaging in patients with melanomas.

Authors:  Lutz Kretschmer; Hans Peter Bertsch; Pawel Bardzik; Johannes Meller; Simin Hellriegel; Kai-Martin Thoms; Michael Peter Schön; Carsten Oliver Sahlmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-10-15       Impact factor: 9.236

2.  Risk of Melanoma Recurrence After Diagnosis of a High-Risk Primary Tumor.

Authors:  Lena A von Schuckmann; Maria Celia B Hughes; Reza Ghiasvand; Maryrose Malt; Jolieke C van der Pols; Vanessa L Beesley; Kiarash Khosrotehrani; B Mark Smithers; Adele C Green
Journal:  JAMA Dermatol       Date:  2019-06-01       Impact factor: 10.282

Review 3.  Importance of tumor load in the sentinel node in melanoma: clinical dilemmas.

Authors:  Alexander C J van Akkooi; Cornelis Verhoef; Alexander M M Eggermont
Journal:  Nat Rev Clin Oncol       Date:  2010-06-22       Impact factor: 66.675

4.  Are We Misdiagnosing Diabetic Foot Osteomyelitis? Is the Gold Standard Gold?

Authors:  Lawrence A Lavery; P Andrew Crisologo; Javier La Fontaine; Kavitha Bhavan; Orhan K Oz; Kathryn E Davis
Journal:  J Foot Ankle Surg       Date:  2019-07       Impact factor: 1.286

Review 5.  Current management of melanoma patients with nodal metastases.

Authors:  Dale Han; Alexander C J van Akkooi; Richard J Straker; Adrienne B Shannon; Giorgos C Karakousis; Lin Wang; Kevin B Kim; Douglas Reintgen
Journal:  Clin Exp Metastasis       Date:  2021-05-07       Impact factor: 4.510

6.  SLN melanoma micrometastasis predictivity of nodal status: a long term retrospective study.

Authors:  Emilia Migliano; Barbara Bellei; Flavio Andrea Govoni; Giovanni Paolino; Caterina Catricalà; Stefania Bucher; Pietro Donati
Journal:  J Exp Clin Cancer Res       Date:  2013-08-01

7.  Data set for pathology reporting of cutaneous invasive melanoma: recommendations from the international collaboration on cancer reporting (ICCR).

Authors:  Richard A Scolyer; Meagan J Judge; Alan Evans; David P Frishberg; Victor G Prieto; John F Thompson; Martin J Trotter; Maureen Y Walsh; Noreen M G Walsh; David W Ellis
Journal:  Am J Surg Pathol       Date:  2013-12       Impact factor: 6.394

8.  Who is to blame for false-negative sentinel node biopsies in melanoma?

Authors:  Vernon K Sondak; Jonathan S Zager
Journal:  Ann Surg Oncol       Date:  2010-03       Impact factor: 5.344

9.  The sentinel node invasion level (SNIL) as a prognostic parameter in melanoma.

Authors:  Lutz Kretschmer; Christina Mitteldorf; Simin Hellriegel; Andreas Leha; Alexander Fichtner; Philipp Ströbel; Michael P Schön; Felix Bremmer
Journal:  Mod Pathol       Date:  2021-06-15       Impact factor: 7.842

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.